Gala vs Noom Med: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Noom Med beats Gala overall, scoring 7.4/10 vs 7/10. Noom Med is more affordable at $69/mo vs $149/mo. Choose Gala for users who want low-cost compounded tirzepatide and a built-i. Choose Noom Med for users who want a tiered entry into glp-1 care — from $69 bra.
A side-by-side comparison of Gala and Noom Med covering pricing, scores, medication types, insurance, and more to help you decide.
Gala
#40 of 42Telehealth platform offering compounded semaglutide and tirzepatide at competitive pricing, plus a paid path to brand semaglutide. Differentiator: a dedicated iOS GLP-1 tracker app for users who want to log dosing, weight, and side effects in one place.
Visit GalaNoom Med
#25 of 42Noom restructured Noom Med in 2026 into 3 tiers: $69/mo branded telehealth (med out-of-pocket), $99-149/mo Microdose GLP-1Rx (low-dose + biomarker monitoring), and the Full GLP-1Rx program ($149 intro → $349/mo on 12-week subscription). Coaching app included at every tier.
Visit Noom Med| Feature | Gala | Noom Med |
|---|---|---|
| Our Score | 7/10 | 7.4/10 |
| Starting Price | $149/mo | $69/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | Yes |
| Best For | Users who want low-cost compounded tirzepatide and a built-in iOS tracker app for daily progress logging | Users who want a tiered entry into GLP-1 care — from $69 branded telehealth to a full $349/mo medication + coaching program, with a new Microdose option at $99-149 |
| Ranking | #40 | #25 |
Pros & Cons Compared
Gala
Pros
- +Compounded tirzepatide as low as $149/mo on the longest commitment plan — among the cheapest tirz options on the market
- +$199/mo entry pricing on a 3-month plan for compounded semaglutide — competitive in the mid-tier
- +Dedicated 'Gala GLP-1 Tracker' iOS app for dosing, weight, and side-effect logging — uncommon among compounded-only platforms
- +Both semaglutide and tirzepatide available, plus a brand-name semaglutide path for users who specifically want FDA-approved
Cons
- −Brand-name semaglutide pricing ($1,299/mo) is significantly above market — NovoCare direct pricing for Wegovy is $349/mo
- −Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness
- −Newer brand (Delaware-registered, limited public company history) — less track record than established platforms like Henry Meds or Sprout
- −No published lab panels or specialty clinical oversight — state-licensed prescriber review is the standard, not differentiated
Noom Med
Pros
- +Tiered 2026 entry — $69/mo branded telehealth tier lets users start with just medication access and the coaching app
- +New Microdose GLP-1Rx program ($99-149/mo) — low-dose GLP-1 + biomarker monitoring for sensitive users
- +Insurance accepted for qualifying plans — can significantly reduce out-of-pocket costs on brand-name meds
- +Industry-leading behavioral coaching app with years of psychology-based weight loss methodology
Cons
- −Tiered pricing creates confusion — $69, $99-149, or $149-349 depending on tier
- −Full GLP-1Rx program requires 12-week subscription ($149 intro rate applies only for the first few weeks)
- −Medication costs on the $69 tier are out-of-pocket — the low tier price is just the platform
- −App coaching still requires real engagement — skip-prone users waste the behavioral value
Our Verdict
Noom Med edges out Gala with a score of 7.4/10 vs 7/10. If budget is your priority, Noom Med starts at $69/mo compared to Gala's $149/mo. Noom Med accepts insurance, which can significantly reduce your out-of-pocket costs. Choose Gala if you want: users who want low-cost compounded tirzepatide and a built-in ios tracker app for daily progress logging. Choose Noom Med if you want: users who want a tiered entry into glp-1 care — from $69 branded telehealth to a full $349/mo medication + coaching program, with a new microdose option at $99-149.